Drug Profile

Research programme: cancer therapeutics - Bluebird Bio/Celgene

Alternative Names: Anti-BCMA CAR T-cells

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator bluebird bio
Class CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Multiple myeloma

Most Recent Events

20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
28 Apr 2019 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Infusion)
15 Mar 2017 Blubird Bio plans a phase I trial of bb 21217 (CRB-402) for Cancer (Blubird Bio Form 10-K, March 2017).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com